Venture Creator
8 January 2025InterHeart: Understanding the interactions between cardiovascular diseases and comorbidities and/or their therapeutic treatments – Pre-announcement
8 January 2025
The IIS Aragón researcher talks in this interview about his work leading the 'Biogenesis and Mitochondrial Pathology' group (GIIS050) and the main challenges they face
Eduardo Ruiz Pesini, Doctor in Biochemistry y present principal investigator Group Mitochondrial Biogenesis and Pathology (GIIS050), has dedicated his career to research for more than 30 years, being part of the Aragón Health Research Institute (IIS Aragón) since its inception.
It was always clear to him that His vocation was research, collaborating with his research group in the genetic diagnosis of rare diseases, becoming the IP in 2018.
What lines of research are being worked on in your group?
One of the main lines of research of our group deals with the Role played by oxidative phosphorylation system (OXPHOS) dysfunction in human health.
What is the main challenge your research group is currently facing?
One of the main challenges we encounter today is the lack of young researchers.
Any ongoing projects that you would like to highlight?
I would like to highlight three projects:
1) OXPHOS and Down Syndrome
2) Mitochondrial Pharmacogenetics of Volatile Anesthetics
3) Rare diseases of the OXPHOS system.
What profiles make up your research team?
The people who make up my group form a interdisciplinary team, including biologists, chemists, biochemists, biotechnologists, pharmacists, veterinarians and physicians.
Why should companies bet on research, and specifically, on your group?
Companies should support research because it means improved health and a potential source of wealth.
Advice for someone starting out in healthcare research?
In the field of research it is essential la vocation, work and study.
